KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Amortization of Deferred Charges (2016 - 2023)

Historic Amortization of Deferred Charges for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q1 2023 value amounting to $532000.0.

  • Supernus Pharmaceuticals' Amortization of Deferred Charges rose 114.07% to $532000.0 in Q1 2023 from the same period last year, while for Dec 2023 it was $532000.0, marking a year-over-year decrease of 7448.44%. This contributed to the annual value of $532000.0 for FY2023, which is 7481.06% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $532000.0 for Q1 2023, which was up 114.07% from $530000.0 recorded in Q4 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Amortization of Deferred Charges peaked at $4.5 million during Q4 2021, and registered a low of $500000.0 during Q2 2022.
  • For the 5-year period, Supernus Pharmaceuticals' Amortization of Deferred Charges averaged around $3.1 million, with its median value being $4.0 million (2019).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Amortization of Deferred Charges surged by 52875.82% in 2019, and later plummeted by 8837.21% in 2022.
  • Supernus Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $4.0 million in 2019, then increased by 4.82% to $4.2 million in 2020, then grew by 6.29% to $4.5 million in 2021, then plummeted by 88.13% to $530000.0 in 2022, then increased by 0.38% to $532000.0 in 2023.
  • Its Amortization of Deferred Charges was $532000.0 in Q1 2023, compared to $530000.0 in Q4 2022 and $529000.0 in Q3 2022.